A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing Alzheimer’s disease.

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for Alzheimer’s disease, a new study shows.

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared to patients taking seven other diabetes drugs, researchers reported.

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type

Semaglutide falls under a class of medications known as glucagon ... MORE: Costco launches weight loss programs that could include Ozempic, Wegovy It can help produce more insulin, which reduces blood sugar and therefore helps control Type 2 diabetes.

Type-2 diabetes patients taking the active ingredient in the drugs, semaglutide, "had a significantly lower risk" of developing the disease, the study found

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.

Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of Alzheimer’s disease.